Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01796626
Other study ID # LUM-ABU-M22-ResurFX-12-01
Secondary ID
Status Completed
Phase N/A
First received February 17, 2013
Last updated August 25, 2014
Start date December 2012
Est. completion date July 2014

Study information

Verified date August 2014
Source Lumenis Ltd.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

At least thirty (30) subjects, Fitzpatrick-Goldman Skin Type I-IV will be enrolled in 2 clinical sites; each clinic will enroll at least 15 subjects.

Subjects should present visible wrinkles and/or striae requiring treatment.

Hypothesis: The M22 ResurFX 1565nm module will improve the appearance of the wrinkles by at least 2 grades on the Fitzpatrick-Goldman Wrinkle and Elastosis Score, and striae by at least 50% using VAS as compared to baseline, for at least 75% of the subjects.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria:

- Able to read, understand and provide written Informed Consent;

- Healthy adult, male or female, 25-55 years of age with Fitzpatrick-Goldman skin type I-IV;

- Having suitable areas of treatment of facial areas to be treated with wrinkles Fitzpatrick-Goldman Wrinkle and Elastosis Score of 3-6 or striae alba present for more than 1 year;

- Able and willing to comply with the treatment/follow-up schedule and requirements;

- Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to enrollment and throughout the course of the study.

Exclusion Criteria:

Any of the following will exclude the subject from the study: skin type V-VI

1. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding;

2. History of post inflammatory hyperpigmentation

3. Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study;

4. Use of photosensitive medication for which light exposure is contraindicated.

5. Use of oral isotretinoin (Accutane®) within 6 months of initial treatment or during the course of the study. Note: skin must regain its normal degree of moisture prior to treatment;

6. Prior treatment, such as chemical peel (especially phenol based) or dermabrasion, in treated area within 3 months of initial treatment or during the course of the study;

7. Prior skin treatment with non-ablative laser or other devices in treated area within 6 months of initial treatment or during the course of the study;

8. Prior use of collagen, fat injections or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 12 months of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants;

9. Prior use of Botox in treatment area within 6 months;

10. Prior ablative resurfacing procedure or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study;

11. Any other surgery in treated area within 9 months of initial treatment or during the course of the study;

12. History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area;

13. Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as Melasma, Chloasma);

14. Concurrent inflammatory skin conditions, including, but not limited to, rosacea of any severity;

15. Open laceration or abrasion of any sort on area to be treated during the course of treatment;

16. Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment;

17. Multiple dysplastic nevi in area to be treated;

18. Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to treatment (as per the patient's physician discretion);

19. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications;

20. Having any form of active cancer at the time of enrollment and during the course of the study or history or skin cancer;

21. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process; Participation in a study of another device or drug within 3 month prior to study enrollment or during this study, and as per the Investigator's discretion, as long as not contradictory to any of the above criteria;

22. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;

23. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
M22 ResurFX module
The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.

Locations

Country Name City State
United States New York Laser & Skin Care New York New York
United States DCLA San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Lumenis Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement Investigator subjective evaluation of the extent of wrinkles improvement at the 3 month follow-up visit as assessed by Fitzpatrick-Goldman Wrinkle Class / Elastosis Score classification, striae improvement will be assessed using VAS. 3 months following 3rd treatment No
Secondary Improvement Investigator subjective evaluation of the extent of wrinkles/striae improvement by the investigator at 1 and 6 month follow-up visits as assessed by Fitzpatrick-Goldman Wrinkle Class / Elastosis Score classification, striae improvement will be assessed using VAS. 1 and 6 months following 3rd treatment No
Secondary Blinded improvement Blinded evaluation of wrinkles/striae skin improvement at the 1, 3 and 6 months follow-up as compared to baseline using photographs may be performed at the end of the study. 1 year following study initiation No
Secondary Skin response Investigator subjective evaluation of skin response following each treatment defined as severity of response and the time it took for it subside Following treatment #1, 2 and 3 Yes
Secondary Downtime Downtime defined as the period of time following the procedure during which the subject felt uncomfortable, unwilling or unable to go out in public due to edema and erythema Following treatment #1, 2 and 3 Yes
Secondary Improvement by subject Subject subjective opinion of improvement and satisfaction with the treatment based on a 5 point scale 1, 3 and 6 months follow up No
Secondary Comfort Subject subjective assessment of pain and discomfort associated with treatments using a 10 point VAS scale Following treatment #1, 2 and 3 Yes
Secondary Biopsies Histological analysis of tissue samples with different staining for analysis of changes following treatment 1, 3 and 6 months follow up Yes
Secondary Adverse Events Any adverse events associated with various setting used during the treatment and follow-up period. Following treatment #1, 2 and 3 and all follow up visits Yes
See also
  Status Clinical Trial Phase
Completed NCT01984619 - Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles N/A
Completed NCT01713985 - Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck N/A
Recruiting NCT01586819 - Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A Phase 3
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT02604641 - Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin N/A
Completed NCT01460927 - TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides N/A
Completed NCT01519934 - A Retrospective Study to Evaluate the Effectiveness of the Ulthera System N/A
Completed NCT03811756 - The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT04988412 - The Effect of 12-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT02913547 - Silk'n HST for Wrinkle Reduction - Clinical Study Protocol N/A
Active, not recruiting NCT02019004 - A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles N/A
Completed NCT02340078 - A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection N/A
Completed NCT01283464 - Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles Phase 2
Completed NCT01034956 - Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections N/A
Completed NCT02425943 - Sculptra Aesthetic Post-Approval Study Phase 4
Recruiting NCT05847530 - Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions N/A
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Completed NCT01859611 - TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides N/A
Completed NCT01297634 - Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle Phase 4
Completed NCT05011461 - The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles N/A